4,901 trials
Hypertension · Heart Failure
Primary: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Prazosin — 85.77; 88.37; 92.39; 192.3 nanogram*hour per…
Autistic Disorder · Autism Spectrum Disorder · Child Development Disorders, Pervasive
Primary: Parts 1, 2 and 3: Percentage of Participants With Adverse Events — 2; 2; 2; 4 Participants
NHL · Non Hodgkin Lymphoma · Diffuse Large B Cell Lymphoma
Primary: Number of Participants Experiencing Dose Limiting Toxicity Events — 0; 0; 0 Participants
Renal Impairment
Primary: Area Under the Curve From Time 0 to Infinity (AUC0-inf) of N-hydroxycytidine (NHC) — 11100; 8960 hr*ng/mL
Overweight and Obesity · Academic Acheivement
Primary: Change in Body Mass Index (BMI) Z-score — 0.03; 0.02; 0.06 z-score
Healthy
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab — 13.0; 12.9 micrograms per milliliter (μg/mL)
Cannabis · Cannabis Use · Marijuana
Primary: Mean Peak for Standard Deviation in Lane Position (SDLP) — 1.33; 1.37; 1.42; 1.35 centimeters
Refractory Multiple Myeloma · Relapsed Multiple Myeloma
Primary: Percentage of Participants With Adverse Events (AEs), Including Dose Limiting Toxicities (DLTs) — 100; 100; 75; 100 Percentage of Participants
Opioid Use · Sedative Use
Primary: Change in Subject-Rated Outcome: Visual Analog Scale (VAS) Drug Liking — 7.40; 39.00; 40.80; 24.50 Score on a scale — p=<0.0001
Visual Acuity
Primary: Visual Acuity (logMAR) at 3 Minutes Post Instillation — 0.09; 0.08 LogMAR
Primary Sjögren Syndrome
Primary: Change in The European League Against Rheumatism (EULAR) Sjogren's Syndrome Patient Reported Index (ESSPRI) Score From Baseline to Week 24 — -0.125 score on a scale
Short Bowel Syndrome · Parenteral Nutrition Associated Liver Disease
Primary: Number of Participants With AEs and SAEs Following Administration of NST 6179 — 4; 2; 2; 2 Participants
BRAF V600E Unresectable or Metastatic Melanoma · BRAF V600E Metastatic NSCLC · Melanoma
Primary: Dose Limiting Toxicities (DLTs) Experienced During Cycle 1 — 0 participants
Carcinoma, Hepatocellular
Primary: Part 1: Number of Participants With Dose-Limiting Toxicities (DLTs) — 0 Participants
Cystic Fibrosis
Primary: The Median for Lefamulin and Its Main Metabolite BC-8041 for PK Plasma Parameter Tmax in Cystic Fibrosis (CF) Patients. — 2.00; 0.583; 1.517; 1.500 hours